A Study to Investigate Mepolizumab in the Treatment of Eo... | NCT02020889

Name	Class
National Institute of Allergy and Infectious Diseases (NIAID)	NIH

Label	Type	Description	Intervention Names
Mepolizumab 300 mg	Experimental	Each subject will receive mepolizumab 300 mg subcutaneous (SC) injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections (100 mg each- total dose 300 mg); individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.	Biological: Mepolizumab
Placebo	Placebo Comparator	Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections; individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.	Drug: Placebo

Name	Type	Description	Arm Group Labels	Other Names
Mepolizumab	Biological	Mepolizumab will be provided as a lyophilized cake in sterile vials for individual use to be reconstituted with sterile water for Injection, just prior to use.

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Number of Participants in Each Category of Accrued Duration of Remission	Total accrued duration of remission is the accrued number of weeks where Birmingham Vasculitis Activity Score (BVAS) =0 plus prednisolone/prednisone dose <=4 mg/day over the 52 week study treatment period was reported. The accrued duration was categorized into zero, >0 to <12 weeks, 12 to <24 weeks, 24 to <36 weeks and >=36 weeks. Statistical analysis was based on a proportional odds regression model with covariates including treatment group, Baseline prednisolone/prednisone daily dose, Baseline BVAS score and region. Intent-to-Treat (ITT) Population was used for the analysis and was defined as all participants who were randomized and received at least one dose of trial medication. Randomized participants were assumed to have received study treatment unless definitive evidence to the contrary exists. The odds ratio for treatment difference and associated probability (p)-value and 95 percent confidence interval (CI) were calculated.	Up to Week 52
Number of Participants Who Are in Remission at 36 and 48 Weeks	The number of participants who were in remission (i.e ., BVAS=0 and prednisolone /prednisone <=4 mg/day) at both Weeks 36 and 48 of the study treatment period was reported. The statistical analysis was performed using a logistic regression model on ITT Population. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.	Week 36 and Week 48

Secondary Outcomes

Measure	Description	Time Frame
Time to First EGPA Relapse	EGPA relapse was defined as worsening or persistence of active disease since the last visit characterized by active vasculitis or active asthma symptoms and/or signs with a corresponding worsening in Asthma Control Questionnaire-6 (ACQ-6) score or active nasal and/or sinus disease, with a corresponding worsening in at least one of the sino-nasal symptom questions warranting: i) an increased dose of OCS therapy (or other systemic corticosteroid therapy) to >4 mg/day prednisolone total daily dose or equivalent; OR ii) an increased dose or addition of immunosuppressive therapy; OR iii) hospitalization related to EGPA worsening. Participants who completed study, or withdrawn prematurely from the study without experiencing the event were censored. The number of participants with at least one EGPA relapse during the planned study treatment period are presented.

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Informed Consent: Able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form. Subjects must be able to read, comprehend, and write at a level sufficient to complete study related materials.
Age and gender: Male or female subjects age 18 years or older.
EGPA diagnosis: subjects who have been diagnosed with EGPA for at least 6 months based on the history or presence of: asthma plus eosinophilia (>1.0x10^9/Liter and/or >10% of leucocytes) plus at least two of the following additional features of EGPA; a biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation; neuropathy, mono or poly (motor deficit or nerve conduction abnormality); pulmonary infiltrates, non-fixed; sino-nasal abnormality; cardiomyopathy (established by echocardiography or Magnetic Resonance Imaging); glomerulonephritis (haematuria, red cell casts, proteinuria); alveolar haemorrhage (by bronchoalveolar lavage); palpable purpura; anti neutrophil cytoplasmic anti-body (ANCA) positive (Myeloperoxidase or proteinease 3).
History of relapsing OR refractory disease defined as: Relapsing disease:

Subject must have a past history of at least one confirmed EGPA relapse (i.e., requiring increase in oral corticosteroids (OCS) dose, initiation/increased dose of immunosuppressive therapy or hospitalisation) within the past 2 years which occurred at least 12 weeks prior to Screening (Visit 1) whilst receiving a dose of prednisolone (or equivalent) of >=7.5 milligram per day (mg/day). Refractory disease: Either: Failure to attain remission (BVAS=0 and OCS dose <=7.5 mg/day prednisolone or equivalent) within the last 6 months following induction treatment with a standard regimen, administered for at least 3 months. Note: a) Subjects who have received a cyclophosphamide (CYC) induction regimen may be included a minimum of 2 weeks after the last dose of daily oral CYC, or 3 weeks after the last dose of pulsed intravenous CYC prior to Baseline (Visit 2), if their total white blood cells (WBC) is >=4x10^9/Liter (tested at the local laboratory, if necessary) prior to randomisation. b) Subjects who have received a methotrexate, azathioprine, or mycophenolate mofetil induction regimen may be included if on a stable dose for at least 4 weeks prior to Baseline (Visit 2). c) Subjects who have received an induction regimen comprising corticosteroids alone may be included only if they have failed to attain remission after 3 months of treatment AND the corticosteroid dose is >=15 mg/day prednisolone or equivalent for the 4 weeks prior to Baseline (Visit 2). Or: Within 6 months prior to Screening (Visit 1), recurrence of symptoms of EGPA (not necessarily meeting the protocol definition of relapse) whilst tapering OCS, occurring at any dose level >=7.5 mg/day prednisolone or equivalent.

Corticosteroid therapy: Subject must be on a stable dose of oral prednisolone or prednisone of >=7.5 mg/day (but not >50 mg/day) for at least 4 weeks prior to Baseline (Visit 2).
Immunosuppressive therapy: If receiving immunosuppressive therapy (excluding cyclophosphamide) the dosage must be stable for the 4 weeks prior to Baseline (Visit 2) and during the study (dose reductions for safety reasons will be permitted).
ECG measurements: QTc(F)<450 msec or QTc(F)<480 msec for patients with bundle branch block. The QTc is the QT interval corrected for heart rate according to either Bazett's formula (QTcB), Fridericia's formula (QTcF), or another method, machine or manual overread. For subject eligibility and withdrawal decisions, QTcFwill be used. For purposes of data analysis, QTcF will be used as primary though data using both correction formulas will be collected and analysed. The QTc should be based on single or averaged QTc values of triplicate electrocardiograms (ECGs) obtained over a brief recording period.
Female subjects: To be eligible for entry into the study, females of childbearing potential (FCBP) must commit to consistent and correct use of an acceptable method of birth control (as discussed in the protocol) beginning with consent, for the duration of the trial and for 4 months after the last study drug administration.
French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.
Liver Function Tests: obtained at Screening (Visit 1): ALT<2x ULN (upper limit of normal) or if subject is on background methotrexate or azathioprine <3x ULN; AST<2x ULN or if subject is on background methotrexate or azathioprine <3x ULN; Alkaline Phosphatase ≤2.0x ULN;Bilirubin ≤ 1.5x ULN (isolated bilirubin>1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)

Exclusion Criteria:

GPA or MPA: Diagnosed with granulomatosis with polyangiitis (GPA; previously known as Wegener's granulomatosis) or microscopic polyangiitis (MPA).
Organ-threatening EGPA: Organ-threatening EGPA as per European league against rheumatism (EULAR) criteria, i.e., organ failure due to active vasculitis, creatinine >5.8 gram per deciliter (g/dL) (>513 micromole per liter [µmol/L]) within 3 months prior to Screening (Visit 1).
Life-threatening EGPA: Imminently life-threatening EGPA disease defined as any of the following within 3 months prior to Screening (Visit 1); Intensive care required; Severe alveolar haemorrhage or haemoptysis requiring transfusion or ventilation or haemoglobin < 8 gram per liter (g/dL) (<80 g/L) or drop in haemoglobin > 2 g/dL (>20 g/L) over a 48 hour period due to alveolar haemorrhage; Rapidly progressive glomerulonephritis (RPGN) with creatinine > 2.5 milligram per deciliter (mg/dL) (>221 µmol/L) or rise in creatinine > 2 mg/dL (>177 µmol/L) over a 48 hour period; Severe gastrointestinal (GI) involvement, e.g., gangrene, bleeding requiring surgery; Severe central nervous system (CNS) involvement; Severe cardiac involvement, e.g., life-threatening arrhythmia, cardiac failure: ejection fraction < 20%, New York Heart Association Class III/IV (as discussed in protocol), acute myocardial infarction.
Malignancy: A current malignancy or previous history of cancer in remission for less than 12 months prior screening (Subjects that had localized carcinoma (i.e., basal or squamous cell) of the skin which was resected for cure will not be excluded).
Liver disease: Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice), cirrhosis, and known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
Cardiovascular: Subjects who have severe or clinically significant cardiovascular disease uncontrolled with standard treatment including but not limited to: Known ejection fraction of <30%, OR Severe heart failure that meets New York Heart Association Class IV (as discussed in protocol), OR Hospitalised in the 12 months prior to Visit 1 for severe heart failure meeting New York Heart Association Class III (as discussed in protocol), OR Angina diagnosed less than 3 months prior to or at Visit 1 (Screening).
Other concurrent medical conditions: Subjects who have known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory or any other system abnormalities that are not associated with EGPA and are uncontrolled with standard treatment.
Infectious disease: Chronic or ongoing active infectious disease requiring systemic treatment.
Parasitic infection: Subjects with a parasitic infestation within 6 months prior to Screening (Visit 1).
Hepatitis status: Diagnosis of chronic hepatitis B, as evidenced by positive Hepatitis B surface antigen (HBsAg) at Screening (Visit 1). Japan only: Subjects positive for HBsAg , antibodies to HBsAg, i.e., HBsAb, or Hepatitis B core antigen, i.e., HBcAb, at Screening (Visit 1). Note: Subjects with antibodies to HBsAg, i.e., HBsAb positive, only (i.e., negative for HBsAg and HBcAb) with a history of hepatitis B vaccination can be included.
HIV: Subjects with a known human immunodeficiency virus infection.
Hypersensitivity: Subjects with a known allergy or intolerance to a monoclonal antibody or biologic therapy.
Previous mepolizumab: Subjects who have previously received mepolizumab within a 1 year period prior to Screening (Visit 1).
Prohibited medications: Subjects receiving any of the following: OCS: Subject requires an oral corticosteroid dose of >50 mg/day prednisolone/prednisone in the 4-week period prior to Baseline (Visit 2); Intravenous or SC corticosteroids in the 4-week period prior to Baseline (Visit 2); Omalizumab within 130 days prior to Screening (Visit 1); Cyclophosphamide: oral CYC within 2 weeks prior to Baseline (Visit 2) and IV CYC within 3 weeks prior to Baseline (Visit 2), if their total WBC is >=4x10^9/Liter (measured using the local laboratory if necessary); Rituximab within 12 months prior to Screening (Visit 1); in addition, the subject must have shown recovery of peripheral B-cell count to within the normal range; IV or SC immunoglobulin within 6 months prior to Screening (Visit 1); Interferon-α within 6 months prior to Screening (Visit 1); Anti-TNF therapy within 12 weeks prior to Screening (Visit 1); Anti-CD52 (alemtuzumab) within 6 months prior to Screening (Visit 1).
Other laboratory parameter exclusions: Creatinine > 2.5 mg/dL (221 µmol/L); WBC < 4 x10^9/Liter, Platelet count <120,000/millimetre cube (mm^3), Haemoglobin <8 g/dL (<80 g/L)
Pregnancy: Subjects who are pregnant or breastfeeding. Subjects should not be enrolled if they plan to become pregnant during the time of study participation.
Alcohol/substance abuse: A history (or suspected history) of alcohol misuse or substance abuse within 2 years prior to Screening (Visit 1).
Other investigational product: Subjects who have received treatment with an investigational drug within the past 30 days or 5 terminal phase half-lives of the drug whichever is longer, prior to Screening (Visit 1) (this also includes investigational formulations of marketed products).
Other clinical study: Subject is currently participating in any other interventional clinical study.
Adherence: Subjects who have known evidence of lack of adherence to controller medications and/or ability to follow physician's recommendations.
French subjects: the French subject has participated in any study using an investigational drug during the previous 30 days or 5 half-lives (whichever is longer).

Name	Affiliation	Role
GSK Clinical Trials	GlaxoSmithKline	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
GSK Investigational Site		Denver	Colorado	80206	United States
GSK Investigational Site

PubMed Identifier	Type	Citation	Retractions
28514601	Derived	Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA, Moosig F, Specks U, Cid MC, Luqmani R, Brown J, Mallett S, Philipson R, Yancey SW, Steinfeld J, Weller PF, Gleich GJ; EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017 May 18;376(20):1921-1932. doi: 10.1056/NEJMoa1702079.

ID	Title	Description
FG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
FG001	Mepolizumab 300mg

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Number of Participants in Each Category of Accrued Duration of Remission

Total accrued duration of remission is the accrued number of weeks where Birmingham Vasculitis Activity Score (BVAS) =0 plus prednisolone/prednisone dose <=4 mg/day over the 52 week study treatment period was reported. The accrued duration was categorized into zero, >0 to <12 weeks, 12 to <24 weeks, 24 to <36 weeks and >=36 weeks. Statistical analysis was based on a proportional odds regression model with covariates including treatment group, Baseline prednisolone/prednisone daily dose, Baseline BVAS score and region. Intent-to-Treat (ITT) Population was used for the analysis and was defined as all participants who were randomized and received at least one dose of trial medication. Randomized participants were assumed to have received study treatment unless definitive evidence to the contrary exists. The odds ratio for treatment difference and associated probability (p)-value and 95 percent confidence interval (CI) were calculated.

ITT Population

Posted

Count of Participants

Participants

Up to Week 52

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants	OG00068 OG00168

Title

Denominators

Categories

Zero

Title	Measurements
	OG00055 OG00132

>0 to <12 weeks

Title	Measurements
	OG000

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001		Proportional odds regression model	Proportional odds regression model with covariates including treatment group, Baseline prednisolone/prednisone daily dose, Baseline BVAS score, region	<0.001		Odds Ratio (OR)	5.91			2-Sided	95	2.68	13.03			Mepolizumab 300mg/Placebo		Other

Primary

Number of Participants Who Are in Remission at 36 and 48 Weeks

The number of participants who were in remission (i.e ., BVAS=0 and prednisolone /prednisone <=4 mg/day) at both Weeks 36 and 48 of the study treatment period was reported. The statistical analysis was performed using a logistic regression model on ITT Population. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.

ITT Population

Posted

Number

Participants

Week 36 and Week 48

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants	OG000

Secondary

Time to First EGPA Relapse

EGPA relapse was defined as worsening or persistence of active disease since the last visit characterized by active vasculitis or active asthma symptoms and/or signs with a corresponding worsening in Asthma Control Questionnaire-6 (ACQ-6) score or active nasal and/or sinus disease, with a corresponding worsening in at least one of the sino-nasal symptom questions warranting: i) an increased dose of OCS therapy (or other systemic corticosteroid therapy) to >4 mg/day prednisolone total daily dose or equivalent; OR ii) an increased dose or addition of immunosuppressive therapy; OR iii) hospitalization related to EGPA worsening. Participants who completed study, or withdrawn prematurely from the study without experiencing the event were censored. The number of participants with at least one EGPA relapse during the planned study treatment period are presented.

ITT Population

Posted

Number

Participants

Up to Week 52

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Secondary

Number of Participants in Each Category of Average Daily Prednisolone/Prednisone Dose During the Last 4 Weeks of the Study Treatment Period.

The number of participants with an average daily prednisolone/prednisone dose during the last 4 weeks of the Study Treatment Period (48 through 52) was calculated. The average dose was categorized into zero, >0 to <=4.0mg, >4.0 to <=7.5mg and >7.5mg. The statistical analysis was performed using a proportional odds regression model with Baseline covariates of treatment group, Baseline prednisolone/prednisone daily dose, Baseline BVAS score and region and the comparison between treatment groups was presented as an odds ratio, p-value and 95 percent CI.

ITT Population

Posted

Count of Participants

Participants

Week 48 and Week52

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts

Secondary

Number of Participants Who Achieved Remission Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period

The number of participants who achieved remission (i.e., BVAS=0 and prednisolone/prednisone<=4 mg/day) within the first 24 weeks and remain in remission for the remainder of the study treatment period was reported. The statistical analysis was performed using a logistic regression model on ITT Population. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.

ITT Population

Posted

Number

Participants

Up to Week 52

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants

Secondary

Number of Participants in Each Category of Accrued Duration of Remission

Total accrued duration of remission, i.e., the accrued number of weeks where Birmingham Vasculitis Activity Score (BVAS) =0 plus prednisolone/prednisone dose <=7.5mg/day over the 52 week study treatment period was reported. BVAS is a validated, clinician-completed tool used for the comprehensive multisystem clinical assessment of disease activity in systemic vasculitis. The duration was categorized into zero, >0 to <12 weeks, 12 to <24 weeks, 24 to <36 weeks and >=36 weeks. Statistical analysis was performed on ITT Population and was based on a proportional odds regression model with covariates including treatment group, Baseline prednisolone/prednisone daily dose, Baseline BVAS score and region. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.

ITT Population

Posted

Count of Participants

Participants

Up to Week 52

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Secondary

Number of Participants Who Are in Remission at 36 and 48 Weeks

The number of participants who were in remission (i.e ., BVAS=0 and prednisolone /prednisone <=7.5mg/day) at both Weeks 36 and 48 of the study treatment period was reported. The statistical analysis was performed using a logistic regression model on ITT Population. The odds ratio for treatment difference and associated p-value and 95 percent CI were calculated.

ITT Population

Posted

Number

Participants

Week 36 and Week 48

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants	OG000

Secondary

Number of Participants Who Achieved Remission (BVAS=0 and Prednisolone/Prednisone <=7.5 mg/Day) Within the First 24 Weeks and Remained in Remission for the Remainder of the Treatment Period

ITT Population

Posted

Number

Participants

Up to Week 52

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants

Secondary

Number of Participants With Local and Systemic Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs including systemic allergic and non-allergic reactions as well as local site injection-related reactions were counted throughout treatment phase and follow up phase. Systemic allergic reactions included Facial paralysis, flushing, hypersensitivity and rash pruritic. Injection related reactions were considered as systemic non-allergic reactions. Local site reactions included injection site bruising, erythema, pain and reaction. The analysis was performed on Safety Population which comprised of all participants who receive at least one dose of study treatment.

Safety Population

Posted

Number

Participants

Up to Week 52

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Secondary

Change From Baseline in Clinical Chemistry Parameters of Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.), Aspartate Aminotransferase (AST), Creatinine Kinase, Gamma Glutamyl Transaminase (GGT) and Lactate Dehydrogenase (Dehydro) Levels

Blood samples were collected to evaluate change from Baseline in ALT, Alk.phosph., AST, creatinine kinase, GGT and lactate dehydro values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Safety population

Posted

Mean

Standard Deviation

International Unit per Liter (IU/L)

Baseline and up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Secondary

Change From Baseline in Clinical Chemistry Parameters of Albumin and Protein Levels

Blood samples were collected to evaluate change from Baseline in albumin and protein levels values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Safety Population

Posted

Mean

Standard Deviation

gram per liter (g/L)

Baseline and up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants

Secondary

Change From Baseline in Clinical Chemistry Parameters of Direct, Indirect and Total Bilirubin and Creatinine Levels

Blood samples were collected to evaluate change from Baseline in direct, indirect and total bilirubin and creatinine values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Safety Population

Posted

Mean

Standard Deviation

micromole per liter (µmol/L)

Baseline and up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants

Secondary

Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, High Density Lipoprotein (HDL) Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, Phosphorus, Potassium, Sodium, Urea Nitrogen and Very Low Density Lipoprotein (VLDL) Cholesterol Levels

Blood samples were collected to evaluate change from Baseline in calcium, chloride, cholesterol, glucose, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, phosphorus, potassium, sodium, urea nitrogen and very low density lipoprotein (VLDL) cholesterol values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured. NA indicates that data were not available.

Safety Population

Posted

Mean

Standard Deviation

millimoles per liter (mmol/L)

Baseline and up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Secondary

Change From Baseline in Clinical Chemistry Parameter of Troponin Levels

Blood samples were collected to evaluate change from Baseline in troponin values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Safety Population

Posted

Mean

Standard Deviation

µg/L

Baseline and up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants

Secondary

Change From Baseline in Hematology Parameters of Basophils, Eosinophil, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets Levels

Blood samples were collected to evaluate change from Baseline in basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelet values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Safety Population

Posted

Mean

Standard Deviation

10^9 cells/L

Baseline and up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants

Secondary

Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin Concentration (MCHC) and Hemoglobin Levels

Blood samples were collected to evaluate change from Baseline in MCHC and hemoglobin values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Safety Population

Posted

Mean

Standard Deviation

g/L

Baseline and up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants

Secondary

Change From Baseline in Hematology Parameters of Mean Corpuscle Volume (MCV) Levels

Blood samples were collected to evaluate change from Baseline in MCV values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Safety Population

Posted

Mean

Standard Deviation

femtoliter (fL)

Baseline and up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants

Secondary

Change From Baseline in Hematology Parameters of Mean Corpuscle Hemoglobin (MCH) Levels

Blood samples were collected to evaluate change from Baseline in MCH values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Safety Population

Posted

Mean

Standard Deviation

Picogram (pg)

Baseline and up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants

Secondary

Change From Baseline in Hematology Parameters of Erythrocytes Levels

Blood samples were collected to evaluate change from Baseline in erythrocytes values at Baseline throughout the 52 weeks study treatment and 8-weeks follow up period. Baseline values were taken at Visit 2 and change from Baseline was defined as post-dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Safety Population

Posted

Mean

Standard Deviation

10^12 cells/L

Baseline and up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants

Secondary

Number of Participants With Anti-Mepolizumab Antibodies

Blood samples were collected for the determination of anti-Mepolizumab antibodies. Participants who showed presence of anti-Mepolizumab antibody were termed as 'positive' and those who did not have anti-Mepolizumab antibody in blood sample were termed as 'negative'. Participants who did not have a positive ADA assay prior to the first dose of investigational product were included in the analysis.

Safety Population

Posted

Number

Participants

Up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants	OG000

Secondary

Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Levels

SBP and DBP were measured from Baseline throughout follow-up (till Week 60) before injection with the participant sitting, having rested in this position for at least 5 minutes before reading. The Baseline value was taken at Visit 2 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Safety Population

Posted

Mean

Standard Deviation

millimeter of mercury (mm of Hg)

Baseline up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants

Secondary

Change From Baseline in Pulse Rate

Pulse rate was measured from Baseline throughout follow-up (till Week 60) before injection with the participant sitting, having rested in this position for at least 5 minutes before reading. The Baseline value was taken at Visit 2 and change from Baseline was defined as post dose visit value minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Safety Population

Posted

Mean

Standard Deviation

beats per minute (bpm)

Baseline and up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants

Secondary

Change From Baseline in Body Temperature

Body temperature was measured from Baseline throughout follow-up (till Week 60). The Baseline value was taken at Visit 2 and change from Baseline was defined as post dose visit value minus Baseline value. The analysis was performed on Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Mean and standard deviation (SD) were measured.

Safety Population

Posted

Mean

Standard Deviation

Degree celsius

Baseline and up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants	OG000

Secondary

Mean Change From Baseline in QT Interval Corrected by Fridericia's Method (QTcF) and QT Interval Corrected by Bazett's Method (QTcB) Values

Single measurements of 12-lead electrocardiogram (ECGs) were obtained after 5 minutes rest in a supine position at Baseline throughout the 52 weeks treatment period and 8 weeks follow-up period using an ECG machine. Mean change from Baseline in QTcF and QTcB values were measured. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Safety Population

Posted

Mean

Standard Deviation

milliseconds (msec)

Baseline and up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants

Secondary

Maximum Change From Baseline in QTcF and QTcB Values

Single measurements of 12-lead ECGs were obtained after 5 minutes rest in a supine position at Baseline throughout the 52 weeks treatment period and 8 weeks follow-up period using an ECG machine. Maximum change from Baseline in QTcF and QTcB values were measured.

Safety Population

Posted

Mean

Standard Deviation

msec

Baseline and up to Week 60

ID	Title	Description
OG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
OG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.

Units	Counts
Participants	OG000

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Influenza	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0002 affected68 at risk EG0010 affected68 at risk
Pneumonia	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0002 affected68 at risk EG0010 affected68 at risk
Appendicitis	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Bronchitis	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Cellulitis	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Corona virus infection	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Enterococcal infection	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Gastroenteritis	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Herpes zoster	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Lower respiratory infection	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0002 affected68 at risk EG0010 affected68 at risk
Parainfluenzae virus infection	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Perirectal abscess	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Pneumonia bacterial	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Respiratory tract infection	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Urinary tract infection	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Asthma	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0004 affected68 at risk EG0012 affected68 at risk
Acute respiratory failure	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0002 affected68 at risk EG0010 affected68 at risk
Lung infiltration	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Pneumonia aspiration	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Respiratory failure	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Cerebellar ischaemia	Nervous system disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Dizziness	Nervous system disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Facial paralysis	Nervous system disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Facial paresis	Nervous system disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Lacunar infarction	Nervous system disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Nystagmus	Nervous system disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Pachymeningitis	Nervous system disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Toxic encephalopathy	Nervous system disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Cardiac arrest	Cardiac disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Coronary artery disease	Cardiac disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Stress cardiomyopathy	Cardiac disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Hernia	General disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Pyrexia	General disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Allergic granulomatous angiitis	Immune system disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Hypersensitivity	Immune system disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Road traffic accident	Injury, poisoning and procedural complications	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Spinal fracture	Injury, poisoning and procedural complications	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Abdominal pain	Gastrointestinal disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Back pain	Musculoskeletal and connective tissue disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0011 affected68 at risk
Testis cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Mental status changes	Psychiatric disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk
Acute kidney injury	Renal and urinary disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0010 affected68 at risk

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Nasopharyngitis	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG00016 affected68 at risk EG00112 affected68 at risk
Sinusitis	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG00011 affected68 at risk EG00114 affected68 at risk
Upper respiratory tract infection	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG00011 affected68 at risk EG00114 affected68 at risk
Bronchitis	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0008 affected68 at risk EG0017 affected68 at risk
Influenza	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0006 affected68 at risk EG0017 affected68 at risk
Respiratory tract infection	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0008 affected68 at risk EG0015 affected68 at risk
Urinary tract infection	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0004 affected68 at risk EG0015 affected68 at risk
Acute sinusitis	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0002 affected68 at risk EG0016 affected68 at risk
Conjunctivitis	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0004 affected68 at risk EG0014 affected68 at risk
Rhinitis	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0003 affected68 at risk EG0015 affected68 at risk
Ear infection	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0006 affected68 at risk EG0011 affected68 at risk
Fungal skin infection	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0003 affected68 at risk EG0014 affected68 at risk
Oral herpes	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0003 affected68 at risk EG0014 affected68 at risk
Gastroenteritis	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0015 affected68 at risk
Otitis media	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0013 affected68 at risk
Viral infection	Infections and infestations	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0013 affected68 at risk
Nausea	Gastrointestinal disorders	MedDRA 19.0	Systematic Assessment	EG00013 affected68 at risk EG00111 affected68 at risk
Diarrhoea	Gastrointestinal disorders	MedDRA 19.0	Systematic Assessment	EG0008 affected68 at risk EG00112 affected68 at risk
Vomiting	Gastrointestinal disorders	MedDRA 19.0	Systematic Assessment	EG0004 affected68 at risk EG00111 affected68 at risk
Abdominal pain upper	Gastrointestinal disorders	MedDRA 19.0	Systematic Assessment	EG0005 affected68 at risk EG0015 affected68 at risk
Abdominal pain	Gastrointestinal disorders	MedDRA 19.0	Systematic Assessment	EG0004 affected68 at risk EG0012 affected68 at risk
Gastrooesophageal reflux disease	Gastrointestinal disorders	MedDRA 19.0	Systematic Assessment	EG0004 affected68 at risk EG0011 affected68 at risk
Dyspepsia	Gastrointestinal disorders	MedDRA 19.0	Systematic Assessment	EG0003 affected68 at risk EG0011 affected68 at risk
Fatigue	General disorders	MedDRA 19.0	Systematic Assessment	EG00010 affected68 at risk EG00110 affected68 at risk
Injection site reaction	General disorders	MedDRA 19.0	Systematic Assessment	EG0007 affected68 at risk EG0019 affected68 at risk
Pyrexia	General disorders	MedDRA 19.0	Systematic Assessment	EG0007 affected68 at risk EG0017 affected68 at risk
Asthenia	General disorders	MedDRA 19.0	Systematic Assessment	EG0003 affected68 at risk EG0015 affected68 at risk
Chest pain	General disorders	MedDRA 19.0	Systematic Assessment	EG0005 affected68 at risk EG0011 affected68 at risk
Injection site pain	General disorders	MedDRA 19.0	Systematic Assessment	EG0003 affected68 at risk EG0012 affected68 at risk
Oedema peripheral	General disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0013 affected68 at risk
Influenza like illness	General disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0013 affected68 at risk
Arthralgia	Musculoskeletal and connective tissue disorders	MedDRA 19.0	Systematic Assessment	EG00012 affected68 at risk EG00115 affected68 at risk
Myalgia	Musculoskeletal and connective tissue disorders	MedDRA 19.0	Systematic Assessment	EG0009 affected68 at risk EG0016 affected68 at risk
Back pain	Musculoskeletal and connective tissue disorders	MedDRA 19.0	Systematic Assessment	EG0006 affected68 at risk EG0018 affected68 at risk
Pain in extremity	Musculoskeletal and connective tissue disorders	MedDRA 19.0	Systematic Assessment	EG0006 affected68 at risk EG0015 affected68 at risk
Neck pain	Musculoskeletal and connective tissue disorders	MedDRA 19.0	Systematic Assessment	EG0002 affected68 at risk EG0018 affected68 at risk
Musculoskeletal pain	Musculoskeletal and connective tissue disorders	MedDRA 19.0	Systematic Assessment	EG0002 affected68 at risk EG0016 affected68 at risk
Joint swelling	Musculoskeletal and connective tissue disorders	MedDRA 19.0	Systematic Assessment	EG0003 affected68 at risk EG0012 affected68 at risk
Muscle spasms	Musculoskeletal and connective tissue disorders	MedDRA 19.0	Systematic Assessment	EG0002 affected68 at risk EG0013 affected68 at risk
Asthma	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0007 affected68 at risk EG00110 affected68 at risk
Cough	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0008 affected68 at risk EG0015 affected68 at risk
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0005 affected68 at risk EG0018 affected68 at risk
Productive cough	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0007 affected68 at risk EG0016 affected68 at risk
Sinus congestion	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0006 affected68 at risk EG0016 affected68 at risk
Wheezing	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0006 affected68 at risk EG0015 affected68 at risk
Nasal congestion	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0005 affected68 at risk EG0014 affected68 at risk
Upper-airway cough syndrome	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0006 affected68 at risk EG0012 affected68 at risk
Dyspnoea	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0004 affected68 at risk EG0011 affected68 at risk
Epistaxis	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0002 affected68 at risk EG0013 affected68 at risk
Sneezing	Respiratory, thoracic and mediastinal disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0013 affected68 at risk
Headache	Nervous system disorders	MedDRA 19.0	Systematic Assessment	EG00012 affected68 at risk EG00122 affected68 at risk
Dizziness	Nervous system disorders	MedDRA 19.0	Systematic Assessment	EG0005 affected68 at risk EG0013 affected68 at risk
Paraesthesia	Nervous system disorders	MedDRA 19.0	Systematic Assessment	EG0003 affected68 at risk EG0014 affected68 at risk
Sinus headache	Nervous system disorders	MedDRA 19.0	Systematic Assessment	EG0003 affected68 at risk EG0012 affected68 at risk
Migraine	Nervous system disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0013 affected68 at risk
Rash	Skin and subcutaneous tissue disorders	MedDRA 19.0	Systematic Assessment	EG0006 affected68 at risk EG0019 affected68 at risk
Pruritus	Skin and subcutaneous tissue disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0016 affected68 at risk
Urticaria	Skin and subcutaneous tissue disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0014 affected68 at risk
Skin lesion	Skin and subcutaneous tissue disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0013 affected68 at risk
Vision blurred	Eye disorders	MedDRA 19.0	Systematic Assessment	EG0002 affected68 at risk EG0014 affected68 at risk
Cataract	Eye disorders	MedDRA 19.0	Systematic Assessment	EG0002 affected68 at risk EG0013 affected68 at risk
Eye pruritus	Eye disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0013 affected68 at risk
Laceration	Injury, poisoning and procedural complications	MedDRA 19.0	Systematic Assessment	EG0002 affected68 at risk EG0013 affected68 at risk
Ligament sprain	Injury, poisoning and procedural complications	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0014 affected68 at risk
Contusion	Injury, poisoning and procedural complications	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0013 affected68 at risk
Vertigo	Ear and labyrinth disorders	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0015 affected68 at risk
Ear discomfort	Ear and labyrinth disorders	MedDRA 19.0	Systematic Assessment	EG0004 affected68 at risk EG0011 affected68 at risk
Alanine aminotransferase increased	Investigations	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0015 affected68 at risk
Weight increased	Investigations	MedDRA 19.0	Systematic Assessment	EG0001 affected68 at risk EG0014 affected68 at risk
Aspartate aminotransferase increased	Investigations	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0013 affected68 at risk
Gamma-glutamyltransferase increased	Investigations	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0013 affected68 at risk
Insomnia	Psychiatric disorders	MedDRA 19.0	Systematic Assessment	EG0004 affected68 at risk EG0012 affected68 at risk
Adrenal insufficiency	Endocrine disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0013 affected68 at risk
Hot flush	Vascular disorders	MedDRA 19.0	Systematic Assessment	EG0000 affected68 at risk EG0013 affected68 at risk

ID	Term
D056648	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
D056647	Systemic Vasculitis
D014657	Vasculitis
D014652	Vascular Diseases
D002318	Cardiovascular Diseases
D006099	Granuloma
D008232	Lymphoproliferative Disorders
D008206	Lymphatic Diseases
D006425	Hemic and Lymphatic Diseases
D017445	Skin Diseases, Vascular
D012871	Skin Diseases
D017437	Skin and Connective Tissue Diseases
D001327	Autoimmune Diseases
D007154	Immune System Diseases

ID	Title	Description
BG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.
BG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.
BG002	Total	Total of all reporting groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Placebo	Participants received placebo injection via subcutaneous (SC) route once every 4 weeks along with standard of care (SOC) drugs up to Week 48.	0	68	18	68	61	68
EG001	Mepolizumab 300mg	Participants received Mepolizumab 300mg injection via SC route once every 4 weeks along with SOC drugs up to Week 48.	1	68	12	68	65	68